TGTX — TG Therapeutics · catalysts, narrative & risks

Overview

TG Therapeutics (NASDAQ: TGTX) is a commercial-stage biotechnology company headquartered in Morrisville, NC, focused on B-cell mediated diseases, anchored by BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS) [7], [18], [23], [26]. As of the latest snapshot it carries a market capitalization of roughly $9 billion [16], [19], [20] and, per the background universe file, is classified as a biotech on NASDAQ.

Recent catalysts (roughly August–November 2026)